Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study

Alberto Hernández, Montserrat Viñals, Asunción Pablos, Francisco Vilás, Peter J Papadakos, Duminda N Wijeysundera, Sergio D Bergese, Marc Vives, Alberto Hernández, Montserrat Viñals, Asunción Pablos, Francisco Vilás, Peter J Papadakos, Duminda N Wijeysundera, Sergio D Bergese, Marc Vives

Abstract

Background: There is still no specific treatment strategies for COVID-19 other than supportive management.

Design: A prospective case-control study determined by admittance to the hospital based on bed availability.

Participants: Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration.

Main outcomes: The primary outcome was time from hospital admission to clinical improvement.

Results: Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p = 0.04, 95% CI -22.25 to -0.42).

Conclusion: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials.

Clinical trial registration number: NCT04444531.

Keywords: COVID-19; Oxygen-ozone therapy; Ozonated blood; Pneumonia; Time to clinical improvement.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival curves.

References

    1. Johns Hopkins University and Medicine; COVID-19 map Johns Hopkins Coronavirus Resource Centre, .
    1. Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
    1. Giunta R., Coppola A., Luongo C., et al. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann. Hematol. 2001;80(12):745–748.
    1. Wu X.N., Zhang T., Wang J., et al. Magnetic resonance diffusion tensor imaging following major ozonated autohemotherapy for treatment of acute cerebral infarction. Neural Regen Res. 2016;11(7):1115–1121.
    1. Borroto R.V., Lima H.L.B., Lima G.S., et al. Prevention of the stroke with the application of ozone therapy. Rev Cub de Med Fis y Rehab. 2013;5(1):3–16.
    1. Pandolfi S., Zammitti A., Franzini M., et al. Effects of oxygen ozone therapy on cardiac function in a patient with a prior myocardial infarction. Ozone Therapy. 2017;2(1) doi: 10.4081/ozone.2017.6745.
    1. Bateman R.M., Sharpe M.D., Ellis C.G. Bench-to-bedside review: microvascular dysfunction in sepsis–hemodynamics, oxygen transport, and nitric oxide. Crit. Care. 2003;7(5):359–373.
    1. Bocci V. Kluwer Academic Publisher; Dordrecht, The Netherlands: 2002. Oxygen-Ozone Therapy: A Critical Evaluation.
    1. Schulz S., Ninke S., Watzer B., et al. Ozone induces synthesis of systemic prostacyclin by cyclooxygenase-2 dependent mechanism in vivo. Biochem. Pharmacol. 2012;83(4):506–513.
    1. Terpos E., Ntanasis-Stathopoulos I., Elalamy I., et al. Hematological findings and complications of COVID-19. Am. J. Hematol. 2020 Apr 13
    1. Yu G., Bai Z., Chen Z., et al. The NLRP3 inflammasome is a potential target of ozone therapy aiming to ease chronic renal inflammation in chronic kidney disease. Int. Immunopharmacol. 2017;43:203–209. doi: 10.1016/j.intimp.2016.12.022.
    1. Sancak E.B., Turkon H., Cukur S., et al. Major ozonated autohemotherapy preconditioning ameliorates kidney ischemia-reperfusion injury. Inflammation. 2016;39(1):209–217.
    1. Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med. Gas Res. 2017;7(3):212–219.
    1. Viebahn-Hänsler R., León Fernández O., Fahmy Z. Ozone in medicine: clinical evaluation and evidence classification of the systemic ozone applications, major autohemotherapy and rectal insufflation, according to the requirements for evidence-based medicine. Ozone Sci. Eng. 2016;38(5):322–345. doi: 10.1080/01919512.2016.1191992.
    1. Jacobs M.T. Adverse effects and typical complications in ozone-oxygen therapy. Ozonachrichten. 1982;1:193–201.
    1. Chirchiglia D., Chirchiglia P., Stroscio C., et al. Suspected pulmonary embolism after oxygen-ozone therapy for low back pain. J. Neurol. Surg. A Cent. Eur. Neurosurg. 2019;80(6):503–506. doi: 10.1055/s-0039-1685197.
    1. Madrid. Community of Madrid, Ministry of Health, Directorate General of Management and Inspection. Director General of Management and Inspection, Manuel Molina Muñoz. Letter of March 9, 2009 addressed to AEPROMO. . Members area, legislation, Spain.
    1. Carsana L., Sonzogni A., Nasr A., et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. Lancet Infect. Dis. 2020;S1473–3099(20):30434–30435.
    1. J.A. Rubano, P.T. Jasinski, D.N. Rutigliano, et al., Tracheobronchial Slough, a Potential Pathology in Endotracheal Tube Obstruction in Patients With Coronavirus Disease 2019 (COVID-19) in the Intensive Care Setting, Ann Surg. 2020, 10.1097/SLA.0000000000004031.
    1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720.
    1. Delvaeye M., Conway E.M. Coagulation and innate immune responses: Can we view them separately? Blood. 2009;114(12):2367–2374.
    1. Zheng Z., Dong M., Hu K. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. J. Med. Virol. 2020
    1. Hernández A., Viñals M., Isidoro T., et al. Potential role of oxygen-ozone therapy in treatment of COVID-19 pneumonia. Am J Case Rep. 2020;21:e925849. doi: 10.12659/AJCR.925849.
    1. Franzini M., Valdenassi L., Ricevuti G., et al. Oxygen-ozone (O2–O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported. Int. Immunopharmacol. 2020;88:106879. doi: 10.1016/j.intimp.2020.106879.
    1. C. Tascini, G. Sermann, A. Pagotto, et al., Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience, Int. Emerg. Med. 2020. Nov 1, doi: .
    1. Hu B., Zheng J., Liu Q., Yang Y., Zhang Y. The effect and safety of ozone autohemotherapy combined with pharmacological therapy in postherpetic neuralgia. J. Pain Res. 2018;11:1637–1643.
    1. Wang Y., Zhang D., Du G., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, Multicentre Trial. Lancet. 2020;395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9.
    1. Hernandez A., Papadakos P.J., Torres A., et al. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19. Rev. Esp. Anestesiol. Reanim. 2020;67(5):245–252.
    1. Fernández-Cuadros M.E., Albaladejo-Florín M.J., Peña-Lora D., Álava-Rabasa S., Pérez-Moro O.S. Ozone (O3) and SARS-CoV-2: physiological bases and their therapeutic possibilities according to COVID-19 evolutionary stage. SN Compr. Clin Med. 2020::1–9. doi: 10.1007/s42399-020-00328-7.
    1. Rowen R.J., Robins H. A plausible, “Penny” costing effective treatment for corona virus - ozone therapy. J. Infect. Dis. Epidemiol. 2020;6:113.
    1. Valdenassi L., Franzini M., Ricevuti G., Rinaldi L., Galoforo A.C., Tirelli U. Potential mechanisms by which the oxygen-ozone (O2–O3) therapy could contribute to the treatment against the coronavirus COVID-19. Eur. Rev. Med. Pharmacol. Sci. 2020;24(8):4059–4061.
    1. Bocci V., Aldinucci C. Biochemical modifications induced in human blood by oxygenation-ozonation. J. Biochem. Mol. Toxicol. 2006 Jun;20(3):133–138.
    1. WHO. Disinfectants and Disinfection By-Products. Available in: .
    1. Babior B.M., Takeuchi C., Ruedi J., et al. Investigating antibody-catalyzed ozone generation by human neutrophils. Proc. Natl. Acad. Sci. USA. 2003;100(6):3031–3034.
    1. Wentworth P., Jr., McDunn J.E., Wentworth A.D., et al. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science. 2002;298(5601):2195–2199.
    1. Notarangelo L., Casanova J.L., Fisher A., et al. Primary immunodeficiency diseases: an update. J. Allergy Clin. Immun. 2004;114(3):677–687.
    1. Paulesu L., Luzzi E., Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF-alpha) on human leucocytes. Lymphokine Cytokine Res. 1991;10(5):409–412.
    1. Diaz-Luis J., Menendez-Cepero S., Diaz-Luis A., et al. In vitro effect of ozone in phagocytic function of leucocytes in peripheral blood. JO3T. 2015;1 Available from: .
    1. Frush B.W., Li Z., Stiles J.V., et al. Ozone primes alveolar macrophage-derived innate immunity in healthy human subjects. J. Allergy Clin. Immunol. 2016;138(4):1213–1215. doi: 10.1016/j.jaci.2016.03.05.
    1. V. Gérard, M.D. Sunnen, SARS and ozone therapy: Theoretical considerations [cited in 2003]. Available from: .
    1. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi: 10.1007/s00134-020-05985-9.
    1. Sagai M., Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Med. Gas Res. 2011;1:29. doi: 10.1186/2045-9912-1-29.
    1. Pecorelli A., Bocci V., Acquaviva A., et al. Nrf2 activation is involved in ozonated human serum upregulation of HO-1 in endothelial cells. Toxicol. Appl. Pharmacol. 2013;267(1):30–40. doi: 10.1016/j.taap.2012.12.001.
    1. Re L., Martínez-Sánchez G., Bordicchia M., et al. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo. A preliminary result? Eur. J. Pharmacol. 2014;742:158–162.
    1. Chang K.W., Sheng Y., Gombold J.L. Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein. Virology. 2000;269(1):212–224.
    1. Madu I.G., Belouzard S., Whittaker G.R. SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. Virology. 2009;393(2):265–271.
    1. Liao Y., Zhang S.M., Neo T.L., et al. Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. Biochemistry. 2015;54(9):1819–1830. doi: 10.1021/bi501352u.
    1. Dussault P.H., George A.D., Trullinger T.K. Peroxides as oxidative enzyme inhibitors: Mechanism-based inhibition of a cysteine protease by an amino acid ozonide. Bioorg. Med. Chem. Lett. 1999;9(22):3255–3258.
    1. A. Hernández, M. Viñals, A. Pablos, et al., Ozone therapy for patients with COVID-19 pneumonia: a Quasi-Randomized Controlled Trial, medRxiv, 2020, 2020.06.03.20117994.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir